https://pepsreview.com/articles/cureus-faers-musculoskeletal-signals-glp-1-study-2026 PepsReview en 2026-09-23 FAERS, semaglutide safety, tirzepatide adverse events, liraglutide, musculoskeletal signals, pharmacovigilance, GLP-1 side effects, incretin safety https://pepsreview.com/articles/viking-vk2735-monthly-maintenance-dosing-trial-2026 PepsReview en 2026-09-23 VK2735, Viking Therapeutics, GLP-1 maintenance dosing, weight loss maintenance, monthly GLP-1 dosing, obesity clinical trial, GLP-1/GIP agonist https://pepsreview.com/articles/roche-enicepatide-phase-2-diabetes-trial-results PepsReview en 2026-09-23 enicepatide, Roche, CT-388, GLP-1 GIP agonist, phase 2 diabetes trial, weight loss, incretin, type 2 diabetes https://pepsreview.com/articles/fda-warning-letter-empower-pharmacy-glp-1-production-2026 PepsReview en 2026-09-23 FDA warning letter, Empower Pharmacy, compounded GLP-1, semaglutide, tirzepatide, 503B outsourcing facility, peptide testing https://pepsreview.com/articles/20-state-ags-urge-tighter-glp-1-green-list-oversight PepsReview en 2026-09-22 GLP-1, Green List, FDA import alert, compounded semaglutide, API sourcing, state attorneys general, peptide testing, pharmaceutical supply chain https://pepsreview.com/articles/fda-import-ban-hits-sinopep-subsidiary-suspending-chinese-peptide-api-sales PepsReview en 2026-09-22 Sinopep, FDA import ban, peptide API, Chinese peptide suppliers, semaglutide API, import alert, peptide supply chain, peptide testing https://pepsreview.com/articles/biophytis-oba-study-amendment-bio101-semaglutide-extension PepsReview en 2026-09-21 Biophytis, BIO101, OBA trial, semaglutide, GLP-1, obesity clinical trial, muscle preservation, 20-hydroxyecdysone https://pepsreview.com/articles/oral-glp-1-snacking-effect-smaller-than-injections-study PepsReview en 2026-09-21 oral semaglutide, GLP-1, snacking, appetite, injections, type 2 diabetes, dietary study, muscle mass https://pepsreview.com/articles/novo-investor-strategy-consumer-plans-glp-1-blockbusters PepsReview en 2026-09-21 Novo Nordisk, Novo, GLP-1, Wegovy, semaglutide, Eli Lilly, tirzepatide, obesity market https://pepsreview.com/articles/fda-compounded-glp-1-warnings-data-gaps-analysis PepsReview en 2026-09-21 FDA, compounded GLP-1, semaglutide, tirzepatide, compounding pharmacy, warning letters, counterfeit peptides, adverse events https://pepsreview.com/articles/cagrisema-beats-tirzepatide-head-to-head-phase-3 PepsReview en 2026-09-21 CagriSema, REIMAGINE 5, tirzepatide, semaglutide, cagrilintide, phase 3 trial, obesity drugs, FDA approval https://pepsreview.com/articles/semaglutide-doses-fewer-psychiatric-diagnoses-study PepsReview en 2026-09-21 semaglutide, GLP-1, psychiatric disorders, mood disorders, substance-related disorders, dose-response, mental health, incretin research https://pepsreview.com/articles/glp-1-pipeline-expands-despite-naion-vision-lawsuits PepsReview en 2026-09-21 GLP-1, NAION, vision loss lawsuits, semaglutide, tirzepatide, retatrutide, drug pipeline, incretin research https://pepsreview.com/articles/glp-1-naion-mdl-reaches-216-cases-mounjaro-vision-claims PepsReview en 2026-09-21 Mounjaro, tirzepatide, NAION, vision loss, MDL-3166, GLP-1 lawsuit, eye side effects, Eli Lilly https://pepsreview.com/articles/higher-dose-ozempic-2mg-injection-oral-tablets PepsReview en 2026-09-21 Ozempic, semaglutide, FDA approval, higher dose, oral tablets, GLP-1, type 2 diabetes, counterfeit